In order to make big discoveries, scientists need to take big risks. Grant support from The Mark Foundation for Cancer Research is enabling Michelle Krogsgaard, PhD, associate professor in the Department of Pathology and a member of NYU Langone Health’s Perlmutter Cancer Center, to do just that. Working at the interface of biophysics and immunology, Dr. Krogsgaard and her colleagues are developing mice with humanized T cell receptors, which allow immune cells to recognize mutated proteins produced by tumors. Their research aims to develop improved cancer immunotherapies.
“Our research is aimed at improving current therapies,” Dr. Krogsgaard tells The Mark Foundation blog. “We hope to find ways to make these treatments better at fighting cancer while preventing some of the toxicities, as well as the resistance, that we often see with the therapies we have now.”
Read more from The Mark Foundation.